Literature DB >> 15060190

Pediatric pharmacokinetic data: implications for environmental risk assessment for children.

Gary Ginsberg1, Dale Hattis, Richard Miller, Babasaheb Sonawane.   

Abstract

Pharmacology and toxicology share a common interest in pharmacokinetic data, especially as it is available in pediatric populations. These data have been critical to the clinical pharmacologist for many years in designing age-specific dosing regimens. Now they are being used increasingly by toxicologists to understand the ontogeny of physiologic parameters that may affect the metabolism and clearance of environmental toxicants. This article reviews a wide range of physiologic and metabolic factors that are present in utero and in early postnatal life and that can affect the internal dose of an absorbed chemical and its metabolites. It also presents a child/adult pharmacokinetic database that includes data for 45 therapeutic drugs organized into specific children's age groupings and clearance pathways. Analysis of these data suggests that substantial child/adult differences in metabolism and clearance are likely for a variety of drugs and environmental chemicals in the early postnatal period. These results are also relevant to in utero exposures, where metabolic systems are even more immature, but exposures are greatly modified by the maternal system and placental metabolism. The implications of these child/adult differences for assessing children's risks from environmental toxicants is discussed with special focus on physiologically based pharmacokinetic modeling strategies that could simulate children's abilities to metabolize and eliminate chemicals at various developmental stages.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15060190

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  18 in total

1.  Organ data from the developing Göttingen minipig: first steps towards a juvenile PBPK model.

Authors:  Els Van Peer; Noel Downes; Christophe Casteleyn; Chris Van Ginneken; Arie Weeren; Steven Van Cruchten
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-12-19       Impact factor: 2.745

2.  Neurobehavioral assessment of mice following repeated postnatal exposure to chlorpyrifos-oxon.

Authors:  Toby B Cole; Jenna C Fisher; Thomas M Burbacher; Lucio G Costa; Clement E Furlong
Journal:  Neurotoxicol Teratol       Date:  2012-03-07       Impact factor: 3.763

3.  A mechanistic approach for the scaling of clearance in children.

Authors:  Andrea N Edginton; Walter Schmitt; Barbara Voith; Stefan Willmann
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Neonatal pharmacology: extensive interindividual variability despite limited size.

Authors:  Cuneyt Tayman; Maisa Rayyan; Karel Allegaert
Journal:  J Pediatr Pharmacol Ther       Date:  2011-07

Review 5.  Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.

Authors:  Imke H Bartelink; Carin M A Rademaker; Alfred F A M Schobben; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  Development and evaluation of a generic physiologically based pharmacokinetic model for children.

Authors:  Andrea N Edginton; Walter Schmitt; Stefan Willmann
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

7.  Early-life exposure to aluminum and fine motor performance in infants: a longitudinal study.

Authors:  Rui Ma; Kefeng Yang; Cheng Chen; Xuanxia Mao; Xiuhua Shen; Linlei Jiang; Fengxiu Ouyang; Ying Tian; Jun Zhang; Ka Kahe
Journal:  J Expo Sci Environ Epidemiol       Date:  2021-02-17       Impact factor: 5.563

Review 8.  Strategic biomarkers for drug development in treating rare diseases and diseases in neonates and infants.

Authors:  Jane P F Bai; Jeffrey S Barrett; Gibert J Burckart; Bernd Meibohm; Hari Cheryl Sachs; Lynne Yao
Journal:  AAPS J       Date:  2013-01-19       Impact factor: 4.009

Review 9.  Pharmacokinetics of intravenous omeprazole in critically ill paediatric patients.

Authors:  Maria Jose Solana; Jesús López-Herce
Journal:  Eur J Clin Pharmacol       Date:  2009-12-30       Impact factor: 2.953

Review 10.  Long-term consequences of drugs on the paediatric cardiovascular system.

Authors:  Elizabeth Hausner; Monica L Fiszman; Joseph Hanig; Patricia Harlow; Gwen Zornberg; Solomon Sobel
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.